Insulet Q3 revenue beats estimates on strong Omnipod sales

Overview

• U.S. insulin pump maker's Q3 revenue rose 19%, beating analyst expectations

• Q3 net income increased and beat analyst expectations

• Company announced $1 bln share buyback, with $400 mln planned for Q4 2026

Outlook

• Company expects FY 2026 revenue growth of 21% to 22% in constant currency

• Company forecasts FY 2026 U.S. Omnipod revenue growth of 17.5% to 18.5%

• Company sees FY 2026 international Omnipod revenue growth of 32% to 33%

Result Drivers

• OMNIPOD GROWTH - Co said strong Omnipod product sales drove overall revenue increase

• INTERNATIONAL EXPANSION - Co attributed revenue growth to strong demand in international markets

• PRODUCT LAUNCHES - Co said new product launches and expanded engagement platforms contributed to customer growth

Company press release:

Key Details

Analyst Coverage

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", 12 "hold" and no "sell" or "strong sell"

• The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"

• Wall Street's median 12-month price target for Insulet Corporation is $170.00, about 9.8% above its November 3 closing price of $154.86

• The stock recently traded at 21 times the next 12-month earnings vs. a P/E of 23 three months ago

Reuters Recommended Reads

• Nov 2 - Inspire Medical Q3 revenue falls, narrows outlook

• Nov 3 - RxSight Q3 revenue falls on competitive pressures

• Nov 3 - AtriCure Q3 revenue beats expectations on strong sales of pain management and appendage devices

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)